Physician profile
Robert E Barkett
NPI 1346310174
$18,379.40
in general payments reported to CMS, 2019-2025
56 companies · $2,904 in 2025
The $2,904 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,810 · 2020: $1,819 · 2021: $2,262 · 2022: $2,551 · 2023: $2,627 · 2024: $3,406 · 2025: $2,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,826 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,826.26 |
| Education | $110.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,783.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,712.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,362.62 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,268.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,122.70 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,105.55 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $948.27 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Janssen Pharmaceuticals, INC | $941.56 | 2019-2024 | Spravato |
| Axsome Therapeutics, INC. | $759.96 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $749.43 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $726.68 | 2019-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $519.32 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $502.24 | 2024-2025 | Korlym |
| Esperion Therapeutics, INC. | $476.26 | 2020-2025 | Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $434.24 | 2019-2024 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barkett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.